Pharmaxis Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMXSF research report →
Companywww.pharmaxis.com.au
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.
- CEO
- Gary Jonathan Phillips
- IPO
- 2010
- Employees
- 27
- HQ
- Frenchs Forest, NSW, AU
Price Chart
Valuation
- Market Cap
- $31.04M
- P/E
- -1.62
- P/S
- 3.51
- P/B
- 1.92
- EV/EBITDA
- -1.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 53.06%
- Op Margin
- -205.79%
- Net Margin
- -197.05%
- ROE
- -111.57%
- ROIC
- -65.78%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,919,000 · 47.70%
- EPS
- $-0.00 · 75.34%
- Op Income
- $-19,874,000
- FCF YoY
- 23.29%
Performance & Tape
- 52W High
- $0.03
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 0.27
- Avg Volume
- 98.28K
Get TickerSpark's AI analysis on PMXSF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PMXSF Coverage
We haven't published any research on PMXSF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PMXSF Report →